Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2018 2
2019 1
2020 1
2021 3
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody.
Augsberger C, Hänel G, Xu W, Pulko V, Hanisch LJ, Augustin A, Challier J, Hunt K, Vick B, Rovatti PE, Krupka C, Rothe M, Schönle A, Sam J, Lezan E, Ducret A, Ortiz-Franyuti D, Walz AC, Benz J, Bujotzek A, Lichtenegger FS, Gassner C, Carpy A, Lyamichev V, Patel J, Konstandin N, Tunger A, Schmitz M, von Bergwelt-Baildon M, Spiekermann K, Vago L, Jeremias I, Marrer-Berger E, Umaña P, Klein C, Subklewe M. Augsberger C, et al. Blood. 2021 Dec 23;138(25):2655-2669. doi: 10.1182/blood.2020010477. Blood. 2021. PMID: 34280257 Free PMC article.
CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS.
Sakemura RL, Manriquez Roman C, Horvei P, Siegler EL, Girsch JH, Sirpilla OL, Stewart CM, Yun K, Can I, Ogbodo EJ, Adada MM, Bezerra ED, Kankeu Fonkoua LA, Hefazi M, Ruff MW, Kimball BL, Mai LK, Huynh TN, Nevala WK, Ilieva K, Augsberger C, Patra-Kneuer M, Schanzer J, Endell J, Heitmüller C, Steidl S, Parikh SA, Ding W, Kay NE, Nowakowski GS, Kenderian SS. Sakemura RL, et al. Among authors: augsberger c. Blood. 2024 Jan 18;143(3):258-271. doi: 10.1182/blood.2022018905. Blood. 2024. PMID: 37879074 Free PMC article.
Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma.
Patra-Kneuer M, Chang G, Xu W, Augsberger C, Grau M, Zapukhlyak M, Ilieva K, Landgraf K, Mangelberger-Eberl D, Yousefi K, Berning P, Kurz KS, Ott G, Klener P, Khandanpour C, Horna P, Schanzer J, Steidl S, Endell J, Heitmüller C, Lenz G. Patra-Kneuer M, et al. Among authors: augsberger c. Front Immunol. 2023 Jul 31;14:1220558. doi: 10.3389/fimmu.2023.1220558. eCollection 2023. Front Immunol. 2023. PMID: 37600821 Free PMC article.
Blockade of the CD47/SIRPα checkpoint axis potentiates the macrophage-mediated anti-tumor efficacy of tafasitamab.
Biedermann A, Patra-Kneuer M, Mougiakakos D, Büttner-Herold M, Mangelberger-Eberl D, Berges J, Kellner C, Altmeyer S, Bittenbring JT, Augsberger C, Ilieva-Babinsky K, Haskamp S, Beier F, Lischer C, Vera J, Lührmann A, Bertz S, Völkl S, Jacobs B, Steidl S, Mackensen A, Bruns H. Biedermann A, et al. Among authors: augsberger c. Haematologica. 2024 Jun 27. doi: 10.3324/haematol.2023.284795. Online ahead of print. Haematologica. 2024. PMID: 38934068 Free article.
A modular and controllable T cell therapy platform for acute myeloid leukemia.
Benmebarek MR, Cadilha BL, Herrmann M, Lesch S, Schmitt S, Stoiber S, Darwich A, Augsberger C, Brauchle B, Rohrbacher L, Oner A, Seifert M, Schwerdtfeger M, Gottschlich A, Rataj F, Fenn NC, Klein C, Subklewe M, Endres S, Hopfner KP, Kobold S. Benmebarek MR, et al. Among authors: augsberger c. Leukemia. 2021 Aug;35(8):2243-2257. doi: 10.1038/s41375-020-01109-w. Epub 2021 Jan 7. Leukemia. 2021. PMID: 33414484 Free PMC article.
Iwr1 directs RNA polymerase II nuclear import.
Czeko E, Seizl M, Augsberger C, Mielke T, Cramer P. Czeko E, et al. Among authors: augsberger c. Mol Cell. 2011 Apr 22;42(2):261-6. doi: 10.1016/j.molcel.2011.02.033. Mol Cell. 2011. PMID: 21504834 Free article.
SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.
Tahk S, Vick B, Hiller B, Schmitt S, Marcinek A, Perini ED, Leutbecher A, Augsberger C, Reischer A, Tast B, Humpe A, Jeremias I, Subklewe M, Fenn NC, Hopfner KP. Tahk S, et al. Among authors: augsberger c. J Hematol Oncol. 2021 Sep 27;14(1):155. doi: 10.1186/s13045-021-01163-6. J Hematol Oncol. 2021. PMID: 34579739 Free PMC article.
Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells.
Lichtenegger FS, Rothe M, Schnorfeil FM, Deiser K, Krupka C, Augsberger C, Schlüter M, Neitz J, Subklewe M. Lichtenegger FS, et al. Among authors: augsberger c. Front Immunol. 2018 Feb 27;9:385. doi: 10.3389/fimmu.2018.00385. eCollection 2018. Front Immunol. 2018. PMID: 29535740 Free PMC article.
Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML.
Haubner S, Perna F, Köhnke T, Schmidt C, Berman S, Augsberger C, Schnorfeil FM, Krupka C, Lichtenegger FS, Liu X, Kerbs P, Schneider S, Metzeler KH, Spiekermann K, Hiddemann W, Greif PA, Herold T, Sadelain M, Subklewe M. Haubner S, et al. Among authors: augsberger c. Leukemia. 2019 Jan;33(1):64-74. doi: 10.1038/s41375-018-0180-3. Epub 2018 Jun 26. Leukemia. 2019. PMID: 29946192 Free PMC article.
Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial.
Lichtenegger FS, Schnorfeil FM, Rothe M, Deiser K, Altmann T, Bücklein VL, Köhnke T, Augsberger C, Konstandin NP, Spiekermann K, Moosmann A, Boehm S, Boxberg M, Heemskerk MH, Goerlich D, Wittmann G, Wagner B, Hiddemann W, Schendel DJ, Kvalheim G, Bigalke I, Subklewe M. Lichtenegger FS, et al. Among authors: augsberger c. Clin Transl Immunology. 2020 Mar 3;9(3):e1117. doi: 10.1002/cti2.1117. eCollection 2020. Clin Transl Immunology. 2020. PMID: 32153780 Free PMC article.